Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 5OTHER 4NIH 3

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Thoracic 3Head & Neck 3Tumor-Agnostic 2Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1CNS 1Breast 1

Conditions

Fallopian Tube Neoplasms 2Uterine Neoplasms 1Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × adavosertib × Gynecologic × Clear all
NCT02659241 2026-04-15

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
38 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
96 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03668340 2026-01-12

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
49 enrolled
Gynecologic

Uterine Neoplasms

NCT01164995 2023-09-07

M10MKO

The Netherlands Cancer Institute

Phase 2 Completed
24 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡